scholarly journals Self-assembling and self-adjuvanting polymer-peptide conjugates as therapeutic vaccines against cervical cancer

2015 ◽  
Author(s):  
Tzu-Yu Liu
Keyword(s):  
Cervical Cancer ◽  
Therapeutic Vaccines ◽  
Peptide Conjugates ◽  
Self Assembling

Advances in dendritic cell-based therapeutic vaccines for cervical cancer

2007 ◽  
Vol 7 (10) ◽  
pp. 1473-1486 ◽  
Author(s):  
Stefania Bellone ◽  
Sergio Pecorelli ◽  
Martin J Cannon ◽  
Alessandro D Santin
Keyword(s):  
Cervical Cancer ◽  
Dendritic Cell ◽  
Therapeutic Vaccines

scholarly journals Diphenylalanine Motif Drives Self‐assembling in Hybrid PNA‐peptide Conjugates

2021 ◽  
Author(s):  
Carlo Diaferia ◽  
Concetta Avitabile ◽  
Marilisa Leone ◽  
Enrico Gallo ◽  
Michele Saviano ◽  
...  
Keyword(s):  
Peptide Conjugates ◽  
Self Assembling

An enzyme-assisted self-delivery system of lonidamine–peptide conjugates for selectively killing cancer cells

2019 ◽  
Vol 55 (98) ◽  
pp. 14852-14855 ◽  
Author(s):  
Can Wu ◽  
Jing Liu ◽  
Xuan Tang ◽  
Ziran Zhai ◽  
Keming Xu ◽  
...  
Keyword(s):  
Cancer Cells ◽  
Delivery System ◽  
Peptide Conjugates ◽  
Self Assembling

A self-delivery system consisting of lonidamine and a self-assembling peptide was designed for the selective killing of phosphatase-overexpressing cancer cells.

Current research into novel therapeutic vaccines against cervical cancer

2018 ◽  
Vol 18 (4) ◽  
pp. 365-376 ◽  
Author(s):  
Marcelo Nazário Cordeiro ◽  
Rita de Cássia Pereira De Lima ◽  
Francesca Paolini ◽  
Alanne Rayssa da Silva Melo ◽  
Ana Paula Ferreira Campos ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Therapeutic Vaccines ◽  
Novel Therapeutic

Prophylactic human papillomavirus vaccines: the beginning of the end of cervical cancer

2004 ◽  
Vol 14 (5) ◽  
pp. 751-761 ◽  
Author(s):  
W. A. A. Tjalma ◽  
M. Arbyn ◽  
J. Paavonen ◽  
T. R. Van Waes ◽  
J. J. Bogers
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Neutralizing Antibodies ◽  
Hpv Vaccination ◽  
Phase Iii ◽  
Hpv Vaccines ◽  
Therapeutic Vaccines ◽  
The Status ◽  
Prophylactic Vaccines

Persistent infection with one of the oncogenic human papillomavirus (HPV) types is a necessity for the development of cervical cancer. By HPV vaccination, cervical cancer could become a very rare disease. Two types of HPV vaccines can be distinguished: (i) therapeutic vaccines which induce cellular immunity targeted against epithelial cells infected with HPV and (ii) prophylactic vaccines inducing virus-neutralizing antibodies protecting against new but not against established infections. At present, several vaccines have been developed and tested in clinical trials. The vaccines are generally well tolerated and highly immunogenic. The current clinical data indicate that prophylactic vaccines are very effective against new persistent infections and the development of cervical intraepithelial lesions. The protection is type specific. However, the follow-up of the vaccination trials is still short. The effect of HPV vaccines on future cancer incidence will only be known after decades of follow-up. This article will address the status of recently terminated phase II and currently running phase III trials with prophylactic HPV vaccines.

Thiol coupling based synthesis of temperature-sensitive polymer–peptide conjugates with controlled architecture.

2012 ◽  
Vol 1418 ◽  
Author(s):  
Jean-Baptiste Guilbaud ◽  
Aline F. Miller ◽  
Alberto Saiani
Keyword(s):  
Phase Transition ◽  
Molecular Weight ◽  
Low Temperature ◽  
Atom Transfer Radical Polymerization ◽  
Radical Polymerization ◽  
Temperature Sensitive ◽  
Thermoresponsive Polymer ◽  
Peptide Conjugates ◽  
Synthetic Strategy ◽  
Self Assembling

ABSTRACTA synthetic strategy to couple selectively an ionic complementary thiol modified octapeptide, that is able to gel at low temperature, to the thermoresponsive polymer poly(N-isopropylacrylamide) (pNIPAAm) with controlled molecular weight and narrow polydispersity is described. The polymer was synthesized by atom transfer radical polymerization (ATRP) affording halogen functionalized chain ends. This allowed subsequent coupling to a thiol terminated ionic complementary octapeptide via nucleophile substitution. Results indicated that the peptide was covalently attached to the polymer and that both the coil-globule phase transition of pNIPAAm and the gelation properties of the peptide were retained in the conjugated product. This method provides a versatile route for the synthesis of a range of bioconjugate materials with controlled architecture and dual self-assembling and thermoresponsive behavior.

scholarly journals The Burden of Human Papillomavirus Infections Among Women in Nigeria: A Review Update

2016 ◽  
Vol 5 (2) ◽  
pp. 9
Author(s):  
Adesuyi Ayodeji Omoare ◽  
Oluwaseyi Sedowhe Ashaka ◽  
Idris Abdullahi Nasir ◽  
Olajide Olubunmi Agbede
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Cultural Practices ◽  
Population Based ◽  
Multiple Infections ◽  
Therapeutic Vaccines ◽  
Cancer Of The Cervix ◽  
High Risk Hpv ◽  
Quadrivalent Vaccines ◽  
Oncogenic Hpv

Cancer of the cervix is the second largest cause of mortality among women globally with an approximate estimate of over 500,000 new cases annually. Human Papillomavirus (HPV) has been long implicated as a necessary cause of Cervical Cancer (CC) in which 80% of the disease burden occurs in developing countries where organized cytology based programmes have not been feasible. Nigeria has a population of over 47 million women who are at risk of contracting HPV. It is estimated that 14,089 women are diagnosed with Cervical Cancer and 8,240 deaths annually. This review, selected publications on HPV related Cervical Cancer across Nigeria where proper quality controlled molecular methods were used for the diagnosis of HPV. Different genotypes of high risk HPV have been detected with variations across populations. HPV types found associated with women in Nigeria included types; 16,18,31,33,35,52,56 and 68 in disproportionate distribution with cases of multiple infections. Findings from this review revealed that the prevalence of Cervical Cancer is on the increase and factors such as; poverty, ignorance, socio-cultural practices, multiple infections by more than one HPV type, persistent infection, government policy, high cost of vaccines and poor acceptance of vaccines all played important roles in the increased prevalence. There is a need for more population based studies to ascertain specific HPV genotype common to specific population and the need for the development of multivalent therapeutic vaccines over the present prophylactic bivalent or quadrivalent vaccines which does not prevent against all oncogenic HPV genotypes.

scholarly journals Novel Antigenic Targets of HPV Therapeutic Vaccines

Vaccines ◽  
2021 ◽  
Vol 9 (11) ◽  
pp. 1262
Author(s):  
Ditte Rahbæk Boilesen ◽  
Karen Nørgaard Nielsen ◽  
Peter Johannes Holst
Keyword(s):  
Cervical Cancer ◽  
Head And Neck ◽  
Cytotoxic T Cells ◽  
Expression Patterns ◽  
Hpv Infection ◽  
Therapeutic Vaccines ◽  
Screening Programs ◽  
Associated Lesions ◽  
E6 And E7 ◽  
Hpv Oncoproteins

Human papillomavirus (HPV) infection is the cause of the majority of cervical cancers and head and neck cancers worldwide. Although prophylactic vaccines and cervical cancer screening programs have shown efficacy in preventing HPV-associated cervical cancer, cervical cancer is still a major cause of morbidity and mortality, especially in third world countries. Furthermore, head and neck cancer cases caused by HPV infection and associated mortality are increasing. The need for better therapy is clear, and therapeutic vaccination generating cytotoxic T cells against HPV proteins is a promising strategy. This review covers the current scene of HPV therapeutic vaccines in clinical development and discusses relevant considerations for the design of future HPV therapeutic vaccines and clinical trials, such as HPV protein expression patterns, immunogenicity, and exhaustion in relation to the different stages and types of HPV-associated lesions and cancers. Ultimately, while the majority of the HPV therapeutic vaccines currently in clinical testing target the two HPV oncoproteins E6 and E7, we suggest that there is a need to include more HPV antigens in future HPV therapeutic vaccines to increase efficacy and find that especially E1 and E2 could be promising novel targets.

Sign in / Sign up

Export Citation Format

Share Document